The tenure of Marty Makary at the Food and Drug Administration has been defined by a fundamental tension: the clash between the agency’s traditional role as a technocratic shield and Makary’s own desire to dismantle what he calls “medical dogma.” Now, that tension has reached a breaking point. Reports indicate that Donald Trump has signed off on a plan to remove the Johns Hopkins surgeon from his post, though the exact timing of the dismissal remains unclear.
For decades, FDA commissioners have operated as stewards of an institution whose authority rests on its perceived independence. The prevailing logic was simple: the safety of the American food and drug supply must never be seen as a byproduct of presidential preference or political expediency. By treating the agency as a political instrument, Makary has not only alienated career scientists but has managed to anger stakeholders across the political spectrum—from vaping advocates and pharmaceutical giants to pro-life organizations.
On Friday evening, President Trump maintained a distance from the reports, telling White House reporters he knew nothing about Makary’s future. However, the internal turmoil at the agency has become impossible to ignore. Current and former officials describe an organization in chaos, where data-driven decisions are frequently overruled by political directives. Neither Makary nor the White House agreed to comment on the reports of his impending exit.
The Voucher System and Political Leverage
The friction began early in Makary’s term with the introduction of the Commissioner’s National Priority Voucher. Launched in June, the pilot program was ostensibly designed to accelerate the approval of drugs aligning with five “national health priorities.” While the FDA often utilizes expedited review pathways for drugs addressing unmet medical needs, this new program appeared to shift the criteria from clinical necessity to political alignment.
Reporting from STAT News suggests the program functioned as a bargaining chip for the White House. All decisions regarding the awarding of these “golden tickets” were reportedly cleared through the administration, creating a direct link between regulatory speed and political cooperation. The most striking example occurred when Eli Lilly and Novo Nordisk agreed to lower the prices of their GLP-1 weight-loss medications and sell them through a Trump-branded website; on the same day, both companies were granted vouchers for new weight-loss drugs.
Overruling the Career Staff
Beyond the voucher system, Makary and his deputies have been accused of systematically ignoring the advice of the agency’s career scientists to satisfy political goals. This pattern was most evident in the handling of mifepristone, the medication used for medical abortions. Despite promising lawmakers during his confirmation that he would conduct a “solid, hard look” at the drug’s safety data, reports emerged in December that Makary had instructed staff to delay the review until after the midterm elections.
This culture of interference extended to the Center for Biologics Evaluation and Research (CBER). Makary appointed Vinay Prasad to lead the center, replacing an official who had clashed with Secretary Robert F. Kennedy Jr. Over vaccine safety. Under Prasad, the FDA moved to restrict COVID-19 vaccine access for young, healthy populations and briefly blocked the review of a new mRNA flu vaccine. While Prasad argued these moves were based on a need for stronger evidence, the decisions mirrored the personal skepticism of RFK Jr. And were reportedly made against the explicit advice of FDA staff. Prasad has since been pushed out of the agency.
| Event/Policy | Stated Objective | Reported Political Outcome |
|---|---|---|
| National Priority Voucher | Accelerate “priority” drugs | Used as leverage for GLP-1 price cuts |
| Mifepristone Review | Safety data evaluation | Delayed until after midterm elections |
| CBER Leadership Change | Stronger evidence standards | Aligned with RFK Jr.’s vaccine skepticism |
| Flavored Vape Authorization | Youth vaping prevention | Overruled after Trump confrontation |
The Vaping Paradox
Ironically, the catalyst for Makary’s potential downfall may be the one area where he attempted to resist the president’s will. Makary has been a vocal skeptic of flavored vapes, dismissing government data that suggests youth vaping rates have dropped to 5 percent. At a September 2025 press conference, he attacked the “broken CDC” inherited from the previous administration, claiming their methodology was flawed.
According to The Wall Street Journal, Makary personally overruled FDA scientists who recommended authorizing flavored vapes equipped with age-verification features. However, this stance placed him in direct opposition to Donald Trump, who promised during his campaign to save the vaping industry. Following a reported confrontation with the president, the FDA abruptly reversed course and authorized the products Makary had previously blocked.
The Legacy of ‘Blind Spots’
Makary entered the FDA as a reformer. In his 2024 book, Blind Spots, he argued that the agency was bogged down by “medical dogma” and a refusal to adapt to new evidence. Yet, when confronted during a recent CNBC interview about his decision to block a skin-cancer drug, Makary adopted the language of the very bureaucrats he once criticized, claiming he was resisting political pressure from lobbyists and the media.
The irony is that during that specific review, the calls for more data came from longtime FDA officials, not political appointees. By oscillating between ignoring science to please the White House and ignoring science to satisfy his own convictions, Makary has created a precarious precedent. The disparate criticisms he faces—from pro-life groups who feel he was too lenient on abortion to vapers who feel he was too restrictive—are symptoms of a single problem: a commissioner who viewed the FDA’s independence as a hurdle rather than a safeguard.
Disclaimer: This article is for informational purposes only and does not constitute medical or legal advice. For official guidance on drug approvals and health regulations, visit the FDA official website.
The White House has not yet announced a formal leadership change at the FDA. The next critical checkpoint will be the upcoming quarterly agency performance review, where the status of the National Priority Voucher program is expected to be addressed.
Do you believe the FDA should be more responsive to the priorities of the sitting president, or should it remain strictly independent? Share your thoughts in the comments below.
